Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMTVDM Directed COVID-19 Treatment Protocol
NCT04349410Phase 3Completed
- Sponsor
- Camelot Foundation
- Start
- Apr 2020
- Primary completion
- Sep 2020
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, open-label trial of hydroxychloroquine, azithromycin, doxycycline, clindamycin, primaquine and 6 more in coronavirus disease 2019 (COVID-19) (11 arms), sponsored by Camelot Foundation. Primary endpoint: Improvement in FMTVDM Measurement with nuclear imaging at 72 hours. Started Apr 2020; status: completed.
02
Drugs
hydroxychloroquineazithromycindoxycyclineclindamycinprimaquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04349410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04349410.